TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2865152

Group type: EXPERIMENTAL
Intervention: Propranolol, Metoprolol, Pindolol (lipophilic beta-blockers)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (hydrophilic beta-blocker)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29909584

Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous fixation (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional open fixation (Group A)
Number of subjects: 60
Study: 28967376

Group type: EXPERIMENTAL
Intervention: Very Early Mobilisation (VEM)
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 2104
Study: 25682859

Group type: EXPERIMENTAL
Intervention: Routine consultation + individualized risk assessment communication intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine consultation
Number of subjects: 102
Study: 23422370

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 15
Study: 21935377

Group type: EXPERIMENTAL
Intervention: 3% SPL7013 Gel (VivaGel)
Number of subjects: 11
Study: 19752076

Group type: EXPERIMENTAL
Intervention: Rectal dimenhydrinate
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 17179265

Group type: EXPERIMENTAL
Intervention: Lidocaine (2 mg/kg IV for 5 min, followed by 3 mg x kg(‐1) x h(‐1) for 10 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study: 15130166

Group type: EXPERIMENTAL
Intervention: Novel VAS device
Number of subjects: 134

Group type: COMPARATOR
Intervention: Paper VAS
Number of subjects: 134
Study: 11548874

Group type: EXPERIMENTAL
Intervention: Perindopril (4mg/day for 4 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day for 4 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg/day for 4 weeks)
Number of subjects: 21
Study: 9718471

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg single dose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Itraconazole 100 mg for 7 days
Number of subjects: 40
Study: 7925264

Group type: EXPERIMENTAL
Intervention: VDT work (text-editing) for 3 hours
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Optical corrections
Number of subjects: 51

Group type: COMPARATOR
Intervention: Distance viewing (control group) for 3 hours
Number of subjects: 51
Study: 2813011

Group type: EXPERIMENTAL
Intervention: Fasting conditions during Ramadan (Experiment 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fasting conditions (Experiment 2)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nonfasting conditions (Experiment 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nonfasting conditions (Experiment 2)
Number of subjects: 70
Study: 1234410

Group type: EXPERIMENTAL
Intervention: Synovectomy of the knee
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation without operation (Control)
Number of subjects: 0
Study: 30929250

Group type: EXPERIMENTAL
Intervention: LAA amputation
Number of subjects: 21

Group type: COMPARATOR
Intervention: No LAA amputation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 30457018

Group type: EXPERIMENTAL
Intervention: Itopride HCl 150 mg ER pellets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ganaton ER 150 mg OD tablets
Number of subjects: 12
Study: 29231340

Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion on navel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clomiphene
Number of subjects: 40
Study: 25567821

Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 24168427

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention measures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control (pseudotarget disease)
Number of subjects: 0
Study: 21797975

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 162
Study: 19553269

Group type: EXPERIMENTAL
Intervention: Ultrasound screening invitation (invited group)
Number of subjects: 67770

Group type: COMPARATOR
Intervention: Control group not offered screening
Number of subjects: 67770
Study: 16772388

Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (H-IMT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham inspiratory muscle training (S-IMT)
Number of subjects: 33
Study: 15273637

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 72
Study: 11523071

Group type: EXPERIMENTAL
Intervention: Test treatment (three doses)
Number of subjects: 0
Study: 9029644

Group type: EXPERIMENTAL
Intervention: Detection of rotavirus groups A, B, and C using polymerase chain reaction/enzyme immunoassay in biliary atresia patients.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Detection of rotavirus groups A, B, and C using polymerase chain reaction/enzyme immunoassay in control patients.
Number of subjects: 24
Study: 8380631

Group type: EXPERIMENTAL
Intervention: Mitomycin C, vinblastine and cisplatin (MVP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cisplatin plus etoposide
Number of subjects: 28
Study: 6354153

Group type: EXPERIMENTAL
Intervention: Linoleic acid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30896650

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 62
Study: 28721837

Group type: EXPERIMENTAL
Intervention: Progressive resistance training combined with a protein-enriched lean red meat diet (RT+Meat)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (CRT) - ≥1 serving/d (25-30 g) carbohydrates
Number of subjects: 100
Study: 25992660

Group type: EXPERIMENTAL
Intervention: Foam Roll (FOAM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Contract-relax PNF stretching (CRPNF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study: 25084499

Group type: EXPERIMENTAL
Intervention: Stigma reduction intervention (video watched weekly for 4 weeks)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 99
Study: 22562296

Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine 0.4% eyedrops
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Generic artificial tears
Number of subjects: 40

Group type: COMPARATOR
Intervention: No drops (control)
Number of subjects: 40
Study: 18836741

Group type: EXPERIMENTAL
Intervention: Visual and auditory features combined in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory and tactile features combined in Experiment 2
Number of subjects: 0
Study: 17313291

Group type: EXPERIMENTAL
Intervention: 3L-1UB (trained 3 sets in leg exercises and 1 set in upper-body exercises; n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1L-3UB (trained 1 set in leg exercises and 3 sets in upper-body exercises; n = 10)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3L-1UB
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1L-3UB
Number of subjects: 21
Study: 16986068

Group type: EXPERIMENTAL
Intervention: Standard dose of proton pump inhibitor (PPI) until symptoms resolve for NERD or until complete remission for erosive disease.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Half-dose PPI for maintenance treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On-demand therapy with half-dose PPI for NERD patients in remission.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Return to full-dose PPI for relapse of symptoms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term treatment with PPIs.
Number of subjects: 0
Study: 12773078

Group type: EXPERIMENTAL
Intervention: Trivalent chromium supplementation
Number of subjects: 0
Study: 10547214

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 70

Group type: COMPARATOR
Intervention: Soluble human insulin
Number of subjects: 70
Study: 8735555

Group type: EXPERIMENTAL
Intervention: ALVAC-RG (10^4.5 TCID50)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALVAC-RG (10^5.5 TCID50)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HDCV (standard human diploid cell rabies vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALVAC-RG (lowest dose 10^3.5 TCID50)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALVAC-RG (booster dose at day 180)
Number of subjects: 0
Study: 1836227

Group type: EXPERIMENTAL
Intervention: Forced warm air
Number of subjects: 90

Group type: COMPARATOR
Intervention: Warmed cotton blankets
Number of subjects: 90

Group type: COMPARATOR
Intervention: Radiant heat lamps
Number of subjects: 90
Study: 6358282

Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31853633

Group type: EXPERIMENTAL
Intervention: Group-based CBT-I
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Self-help CBT-I
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sleep hygiene control
Number of subjects: 83
Study: 31233507

Group type: EXPERIMENTAL
Intervention: IDA (ivermectin 200 μg/kg, diethylcarbamazine 6 mg/kg, albendazole 400 mg)
Number of subjects: 26836

Group type: COMPARATOR
Intervention: DA (diethylcarbamazine plus albendazole)
Number of subjects: 26836
Study: 28128223

Group type: EXPERIMENTAL
Intervention: Intravenous saline post procedure (Group A)
Number of subjects: 617

Group type: COMPARATOR
Intervention: No intravenous fluids post-procedure (Group B)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 617
Study: 26200619

Group type: EXPERIMENTAL
Intervention: Improvement of malnutrition (IOM)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Reduction of inflammation (ROI)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Both IOM and ROI groups
Number of subjects: 108
Study: 23531998

Group type: EXPERIMENTAL
Intervention: Antioxidant (AO) supplementation for 3 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (PL) for 3 months
Number of subjects: 61
Study: 21755823

Group type: EXPERIMENTAL
Intervention: Immunocapture test
Number of subjects: 211

Group type: COMPARATOR
Intervention: Coombs test
Number of subjects: 211

Group type: COMPARATOR
Intervention: SAT
Number of subjects: 211

Group type: COMPARATOR
Intervention: 2-ME test
Number of subjects: 211
Study: 19426126

Group type: EXPERIMENTAL
Intervention: Mepolizumab given intravenously once a month
Number of subjects: 0
Study: 17173514

Group type: EXPERIMENTAL
Intervention: Acetazolamide (750 mg PO daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no acetazolamide)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (with and without Actz)
Number of subjects: 16
Study: 14505753

Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone administered on day LH+2
Number of subjects: 14
Study: 10833761

Group type: EXPERIMENTAL
Intervention: Internal-frame backpack
Number of subjects: 20

Group type: COMPARATOR
Intervention: External-frame backpack
Number of subjects: 20
Study: 9166270

Group type: EXPERIMENTAL
Intervention: Endoluminal repair
Number of subjects: 117

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 117
Study: 1533941

Group type: EXPERIMENTAL
Intervention: Graded activity program
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 2908814

Group type: EXPERIMENTAL
Intervention: Fenoldopam 50 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fenoldopam 100 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fenoldopam 150 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg + Fenoldopam 100 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: COMPARATOR
Intervention: Metoclopramide 20 mg + Placebo
Number of subjects: 2
Study: 30695836

Group type: EXPERIMENTAL
Intervention: Questionnaire group (QG) - received questionnaires assessing well-being, completed three times on the day of donation and four times over 8 weeks with reminder calls.
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group (CG) - not contacted with a questionnaire.
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Questionnaire group (QG) - received questionnaires assessing well-being.
Number of subjects: 217
Study: 30486849

Group type: EXPERIMENTAL
Intervention: Anodal tDCS with a small active cathode (4 × 4 cm2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Anodal tDCS with a large, functionally inert cathode (10 × 10 cm2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (all montages)
Number of subjects: 18
Study: 27271183

Group type: EXPERIMENTAL
Intervention: Volanesorsen 300 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 25415818

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2 microgram/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50
Study: 22464212

Group type: EXPERIMENTAL
Intervention: Angiographic follow-up at 8 months ± 28 days
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Clinical follow-up alone
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Angiographic follow-up with paclitaxel-eluting stent (PES)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Clinical follow-up with paclitaxel-eluting stent (PES)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Angiographic follow-up with everolimus-eluting stent
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Clinical follow-up with everolimus-eluting stent
Number of subjects: 1002
Study: 20019137

Group type: EXPERIMENTAL
Intervention: Total Body Weight (TBW) group (0.6 g of iodine per kilogram of TBW)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lean Body Weight (LBW) group (0.821 g of iodine per kilogram of LBW)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Blood Volume (BV) group (men, 8.6 g of iodine per liter of BV; women, 9.9 g of iodine per liter of BV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lean Body Weight (LBW) group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Total Body Weight (TBW) group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Blood Volume (BV) group
Number of subjects: 120
Study: 18024370

Group type: EXPERIMENTAL
Intervention: Induction therapy with idarubicin and cytarabine plus lomustine (ICL)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Induction therapy with idarubicin and cytarabine (IC)
Number of subjects: 364
Study: 16118354

Group type: EXPERIMENTAL
Intervention: Preoperative morphine (10 mg IV) and postoperative OMT
Number of subjects: 39

Group type: COMPARATOR
Intervention: Preoperative saline (control) and postoperative OMT
Number of subjects: 39

Group type: COMPARATOR
Intervention: Preoperative saline (control) and postoperative sham manipulative treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Preoperative morphine (10 mg IV) and postoperative sham manipulative treatment
Number of subjects: 39
Study: 11383326

Group type: EXPERIMENTAL
Intervention: 10 mg/d atorvastatin for 10 or more weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1.68 g/d omega-3 FA (ethylesters of eicosapentaenoic and docosahexaenoic acids)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 42
Study: 9734349

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 2145

Group type: COMPARATOR
Intervention: Steroid nonusers
Number of subjects: 2145
Study: 8067227

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Isoflurane and Nitroglycerin)
Number of subjects: 40
Study: 3057655

Group type: COMPARATOR
Intervention: Marevan (Allen & Hanburys)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Warfarin (Petersen)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Coumadin (Boots)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Warfarin (Lennon)
Number of subjects: 12
Study: 29199002

Group type: EXPERIMENTAL
Intervention: Dinner at 2100h (D21)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Divided dinner (DD)
Number of subjects: 14
Study: 29530224

Group type: EXPERIMENTAL
Intervention: BPAC Inc. TIA/stroke electronic decision support (EDS) for GPs
Number of subjects: 291

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 291
Study: 25365753

Group type: EXPERIMENTAL
Intervention: Recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV)
Number of subjects: 20869

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20869
Study: 23298135

Group type: EXPERIMENTAL
Intervention: 500mg resveratrol/day for 30 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21842613

Group type: EXPERIMENTAL
Intervention: Active drug (specific drug not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dose or augmentation agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18073468

Group type: EXPERIMENTAL
Intervention: Multidetector-row CT angiography (CTA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 33
Study: 16467768

Group type: EXPERIMENTAL
Intervention: 200mg itraconazole twice daily during the first week of a 4 weeks cycle for 16 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: 250mg terbinafine twice daily during the first week of a 4 weeks cycle for 16 weeks
Number of subjects: 30
Study: 12845417

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10811148

Group type: EXPERIMENTAL
Intervention: Leg press power and habitual physical activity level
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Leg power
Number of subjects: 80
Study: 8785136

Group type: EXPERIMENTAL
Intervention: Eltanolone
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 76
Study: 2050651

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 205

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 205
Study: 6687578

Group type: EXPERIMENTAL
Intervention: Agiolax (15 mg senna glucosides)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lunelax comp. (25 mg senna glucoside A + B)
Number of subjects: 20
Study: 30735064

Group type: EXPERIMENTAL
Intervention: Constant Power Score
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Traumatic mechanism of injury
Number of subjects: 452
Study: 29504781

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Social Behavior and Network Therapy (SBNT)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 376
Study: 27780504

Group type: EXPERIMENTAL
Intervention: PFNA combined with zoledronic acid injection (5 mg/100 ml via intravenous drip)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (PFNA with 600 mg of Caltrate D and 0.25 mg of alpha ossification alcohol)
Number of subjects: 60
Study: 25278346

Group type: EXPERIMENTAL
Intervention: Dry eye disease patients
Number of subjects: 130

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 130
Study: 23306768

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with biofeedback (BF)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training without biofeedback (PFMT)
Number of subjects: 46
Study: 20826964

Group type: EXPERIMENTAL
Intervention: Epicardial ultrasound scanning with a 10-MHz transducer
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Surgeon's assessment of anastomosis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cardiac anesthesiologist's assessment of anastomosis
Number of subjects: 15
Study: 18853704

Group type: EXPERIMENTAL
Intervention: Ramelteon 1 mg once daily for 4 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ramelteon 2 mg once daily for 4 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ramelteon 4 mg once daily for 4 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg once daily for 4 days
Number of subjects: 75
Study: 15992726

Group type: EXPERIMENTAL
Intervention: Rounded waveform shocks (50 to 500 V)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional waveform shocks (50 to 500 V)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both rounded and conventional waveforms
Number of subjects: 10
Study: 14619332

Group type: COMPARATOR
Intervention: Omalizumab, 300 mg, administered subcutaneously every 4 weeks (three injections) for IgE levels < or = 150 IU/mL and every 3 weeks (four injections) for IgE levels > 150 IU/mL.
Number of subjects: 287
Study: 10476977

Group type: EXPERIMENTAL
Intervention: Sports bra
Number of subjects: 3

Group type: COMPARATOR
Intervention: Fashion bra
Number of subjects: 3

Group type: COMPARATOR
Intervention: Crop top
Number of subjects: 3

Group type: COMPARATOR
Intervention: Bare breasted
Number of subjects: 3
Study: 8733926

Group type: EXPERIMENTAL
Intervention: Strong cue group (context words, line drawings, and stems of target words)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weak cue group (context words and stems of target words without line drawings)
Number of subjects: 0
Study: 1747004

Group type: EXPERIMENTAL
Intervention: 100 mg of fluconazole daily for 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluconazole (open phase)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No fluconazole treatment
Number of subjects: 25
Study: 6341070

Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (PHT, 200 mg/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (PHT, 300 mg/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ, 600 mg/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ, 800 mg/day)
Number of subjects: 6